

## INDEX

---

*Note:* Page numbers in *italics* indicate figures; page numbers followed by t refer to tables.

- $\alpha$ -adrenergic blockade
  - in sexual dysfunction, 106t
  - vasoconstriction with, 124
- Abdominal discomfort
  - clozapine and, 66t
  - quetiapine and, 80t
  - risperidone and, 84t
- Abilify. *See also Aripiprazole.*
  - adverse effects of, 60-61, 61t
  - clinical trials in, 59
  - dopamine effects, 59
  - dosing information for, 56-57t, 59
  - efficacy, 59
  - history and mechanism of action, 58
  - in management of acute psychosis, 170-171t
  - pharmacokinetics, 59
  - SGAD therapy with, 37t
- Abnormal gait, with olanzapine therapy, 74-75t
- Abnormal Involuntary Movement Scale (AIMS), evaluation of antipsychotic
  - side effects in, 48, 49
- Absorption, factors affecting, 227-228
- Acarbose (Precose), antidiabetic mechanism of, 164-165t
- Accidental injury
  - comparative incidence of, in SGAD therapy, 99t
  - with olanzapine therapy, 74-75t
  - with ziprasidone, 88t
- Actos. *See Pioglitazone.*
  - antidiabetic mechanism of, 164-165t
- Acute psychosis. *See Psychiatric emergency.*
- Adherence to drug therapy. *See Noncompliance.*
- Adolescents
  - diagnosing considerations in, 213
  - treatment of psychosis in, 214-216
- Affect, in symptomatology of schizophrenia, 13
- Age, in epidemiology of schizophrenia, 14t
- Aggression
  - in symptomatology of schizophrenia, 25
  - management of, 172
  - medications linked to, 172t
- Agitation
  - in rebound phenomenon, 63
  - in treatment with conventional antipsychotics, 125
  - with aripiprazole, 61t
  - with clozapine, 66t

- Agitation (*continued*)  
 with paliperidone ER, 78t  
 with risperidone, 84t
- Agranulocytosis, with clozapine, 65
- AIMS, See *Abnormal Involuntary Movement Scale*.
- Akathisia  
 comparative incidence of, in SGAD therapy, 99t, 103  
 with aripiprazole, 61t  
 with clozapine, 66t  
 with high-dose antipsychotic therapy, 172  
 with long-acting risperidone, 193-194  
 with olanzapine therapy, 74-75t  
 with ziprasidone, 88t
- AKT1, in vulnerability for schizophrenia, 21t
- Alcohol  
 abuse, with schizophrenia, 220-222  
 association with aggressive behavior, 172t
- Alcoholism, in predisposition to QTc prolongation, 110
- Aliphatics  
 chemical structure of, 118-119  
 in phenothiazine subtyping, 115
- Alogia  
 in differential diagnosis, 28t  
 in negative symptomatology of schizophrenia, 25t
- Alpha-1 receptor, adverse effects with antagonism of, 122t
- Alpha-glucosidase inhibitors, antidiabetic mechanism of, 164-165t
- Altshuler, evaluation of pregnancy and antipsychotic use, 225
- Alzheimer's disease  
 SGAD therapy in, 219  
 psychosis with, in the elderly, 217
- Amantadine, use of, in patients on antipsychotic drugs, 155
- Amaryl. See also *Glimepiride*.  
 antidiabetic mechanism of, 164-165t
- Amblyopia, with olanzapine therapy, 74-75t
- Amenorrhea  
 treatment considerations in, 40-41t  
 with risperidone, 85
- American Diabetes Association  
 diagnostic criteria of, for type 2 diabetes, 157-158, 158t  
 monitoring recommendations of  
 for glucose dysregulation, 154t, 162  
 for lipid profile, 163, 165
- American Psychiatric Association, treatment guidelines of, 35
- Ampakines, potential benefits of, in schizophrenia, 239
- Amphetamines  
 association with aggressive behavior, 172t  
 positive psychotic symptoms with, 16
- Anabolic steroids, association with aggressive behavior, 172t
- Anhedonia  
 in negative symptomatology of schizophrenia, 25t
- Anhedonia (*continued*)  
 in rebound phenomenon, 63  
 with functional brain changes, 16t
- Anorexia, with ziprasidone, 88t
- Anticholinergic side effects  
 comparative incidence of, in SGADs, 100t  
 comparative, with conventional antipsychotic therapy, 122, 123t, 125-126  
 in antipsychotic therapy for the elderly, 218  
 susceptibility to, of elderly patients, 218  
 treatment considerations in, 40-41t, 125
- Anticonvulsant medications  
 association with aggressive behavior, 172t  
 in management of aggression, 172
- Antipsychotic medication  
 introduction of, 15  
 metabolism and distribution of, 228-229
- Anxiety  
 comparative incidence of, in SGAD therapy, 99t  
 in assessment of psychopathology, 44t  
 in symptomatology of schizophrenia, 25  
 with aripiprazole, 61t  
 with paliperidone ER, 78t  
 with risperidone, 84t
- Anxiety disorder  
 treatment of, with antipsychotic drugs, 33  
 with schizophrenia, treatment of, 222-224
- Appetite disturbance, in symptomatology of schizophrenia, 185
- Arcuate, role in effect of antipsychotic drugs, 16, 17
- Aripiprazole  
 adverse effects of, 60-61, 61t  
 as first-line therapy, by comorbidity, 40-41t  
 chemical structure of, 55  
 clinical trials in, 59  
 comparative efficacy of, 94-97, 96t  
 comparative incidence of extrapyramidal side effects in, 98, 102, 104  
 comparative side effects of, 98, 99t, 100t  
 diabetic ketoacidosis in, 161  
 dopamine effects, 59  
 dopamine receptor affinity of, 101  
 dosing information for, 56-57t, 59  
 effect of, on glucose homeostasis, 162  
 effect of, on QTc interval, 111  
 effect on cognition by, 237  
 efficacy, 59  
 history and mechanism of action, 58  
 in adolescents and children with schizophrenia, 214  
 in combination therapy for treatment-resistant schizophrenia, 207t  
 in management of acute psychosis, 170-171t  
 in SGAD therapy, 37t  
 in the elderly, 218, 220

- Aripiprazole (*continued*)
- in treatment algorithm, 38
  - in treatment of aggressive behavior, 173
  - in treatment-resistant schizophrenia, 205
  - in young patients, 97
  - lipid changes with, 165
  - metabolism of, 230t
  - pharmacokinetics, 59
  - potential benefits of new forms of, 182
  - profiles for receptor binding, 54
  - receptor affinity of, 95t
  - relapse with, vs conventional therapy, 242
  - sedative effect, in clinical trials, 112
  - vs risperidone in prevention of relapse, 178
  - weight gain with, 150, 151, 152t
- Arthralgia
- with hepatic changes in antipsychotic therapy, 128
  - with risperidone, 84t
- Articulation impairment, with olanzapine therapy, 74-75t
- Asenapine, in new developments for treating schizophrenia, 250
- Asthma
- with aripiprazole, 61t
  - with olanzapine therapy, 74-75t
  - with quetiapine, 80t
  - with ziprasidone, 88t
- Asymmetry of frontal and occipital lobes, associated with schizophrenia, 15t
- Atropine, in hypersalivation, 68t
- Attention, in schizophrenia, 235
- Auditory symptoms, with functional brain changes, 16t
- Autoimmune disorder, in diagnosis of psychotic disorder, 30t
- Avandia. See *Rosiglitazone*.
- antidiabetic mechanism of, 164-165t
- Avolition
- in differential diagnosis, 28t
  - in negative symptomatology of schizophrenia, 25t
- Avolitional syndrome, 21
- $\beta$ -adrenergic effects, in mechanism for vasoconstriction, 124
- $\beta$ -blocking agents, in management of aggressive behavior, 172
- Back pain
- with olanzapine therapy, 74-75t
  - with quetiapine, 80t
  - with risperidone, 84t
- Barnes Akathisia Rating Scale (BARS), in evaluation of antipsychotic side effects, 48, 49
- BARS. See *Barnes Akathisia Rating Scale*.
- Basal ganglia
- role of, in dopaminergic receptor-deficit hypothesis, 18
  - role of, in effect of antipsychotic drugs, 16, 17
- Benzodiazepines
- association with aggressive behavior, 172t
  - in acute antipsychotic treatment, 35
  - in management of aggressive behavior, 172
  - in schizoaffective disorder, 223, 224
  - in schizophrenia with depression, 223, 224
  - with clozapine therapy, 69
- Benztropine, in hypersalivation, 68t
- Bethanechol
- in treatment of anticholinergic effects of conventional antipsychotics, 125
  - in treatment of sexual disturbance in antipsychotic therapy, 109t
- Bifeprunox, in new developments for treating schizophrenia, 250
- Biguanides, antidiabetic mechanism of, 164-165t
- Biperiden, in hypersalivation, 68t
- Bipolar disorder
- in diagnosis of psychotic disorder, 30t
  - SGAD therapy in, 222-223
  - treatment of, with antipsychotic drugs, 33
- Bizarre delusions, defined, 23t
- Bleuler, Eugene, in early characterization of schizophrenia, 14
- Blonanserin, in new developments for treating schizophrenia, 251
- Blunted affect
- in assessment of psychopathology, 47t
  - in negative symptomatology of schizophrenia, 25t
- Blurred vision, with aripiprazole, 61t
- BPRS. See *Brief Psychiatric Rating Scale*.
- Bradycardia, in predisposition to QTc prolongation, 110
- Brain activation patterns, in treatment-resistant schizophrenia, 199
- Brief Psychiatric Rating Scale (BPRS)
- in assessment of psychopathology, 43, 44-47t
  - in evaluation of SGAD effects in psychiatric emergency, 173
- Broca's area
- impact of functional changes in, 16t
  - role in effect of antipsychotic drugs, 16, 17
- Bromocriptine
- in treatment of NMS, 131-132, 132t
  - in treatment of sexual disturbance in antipsychotic therapy, 109t
- Buspirone
- in schizoaffective disorder, 224
  - in schizophrenia with depression, 224
- Butyrophenones
- as subclass of antipsychotic medication, 116, 118-119
  - chemical structure of, 118-119
  - in pregnancy/lactation, 225
- CAFE study. See *Comparison of Atypicals for First-Episode Psychosis study*.
- Calcium channel blockade, in sexual dysfunction, 106t
- Calgary Depression Rating Scale, comparison of SGAD efficacy by, 97

- Cannabis  
 abuse, with schizophrenia, 220-222  
 association with aggressive behavior, 172t
- Carbamazepine  
 effect of, on metabolism of antipsychotic drugs, 231t  
 effect on drug absorption, 228  
 in schizoaffective disorder, 223  
 in schizophrenia with depression, 223
- Cardiac arrhythmias, treatment considerations in, 40-41t
- Cardiac disease, in predisposition to QTc prolongation, 110
- Cardiomyopathy, with clozapine therapy, 69
- Cardiorespiratory arrest, with clozapine therapy, 69
- Cardiovascular effects  
 comparative, with conventional antipsychotic therapy, 122, 123t  
 with clozapine, 69  
 with olanzapine, 73  
 with quetiapine, 80  
 with risperidone, 83  
 with ziprasidone, 89
- Carpenter, characterization of schizophrenia by, 21
- Cataracts, with quetiapine, 81
- Catatonic type, in categorization of schizophrenia, 26
- Catechol-*O*-methyltransferase val108/158met, in predicting antipsychotic efficacy, 236
- CATIE trial. See *Clinical Antipsychotic Trials for Interventions Effectiveness*.
- Caudate nucleus, role in effect of antipsychotic drugs, 16, 17
- CBT. See *Cognitive behavior therapy*.
- Central adipose tissue, metabolic activity in, 147
- Central nervous system  
 measurement of, in patient evaluation, 15  
 neurotransmitter levels of, 15
- Cerebellar atrophy, associated with schizophrenia, 15t
- CGI. See *Clinical Global Impression*.
- Chest pain  
 with olanzapine therapy, 74-75t  
 with risperidone, 84t
- Children. See *Adolescents*.
- Children's Psychiatric Rating Scale, PANSS in evaluation of treatment, 216
- Chills, with hepatic changes in antipsychotic therapy, 128
- Chlorpromazine  
 adverse effects with, 123t  
 anticholinergic effects of, 125  
 chemical structure of, 118-119  
 contraindicated with ziprasidone, 232  
 dopamine receptor affinity of, 101  
 dosing guidelines for, 120-121t  
 effect on cognition by, 237  
 for acute agitation, 168
- Chlorpromazine (*continued*)  
 history of, 33, 115  
 in conventional antipsychotic therapy, 36t  
 in determination dosage equivalence, 116, 214  
 in therapy for treatment-resistant schizophrenia, 198  
 incidence of type 2 diabetes with, 157  
 orthostatic hypotension with, 124  
 weight gain with, 149, 151
- Cholestyramine, effect on drug absorption, 227
- Cholinergic antagonism, in sexual dysfunction, 106t
- Cholinesterase inhibitors, potential benefits of, in schizophrenia, 239
- Cigarette smoking, effect of, on metabolism of antipsychotic drugs, 231t
- Cimetidine, effect of, on metabolism of antipsychotic drugs, 231t
- Cingulate gyrus, impact of functional changes in, 16t
- Circumstantiality, in thought disorder, 24t
- Cisapride, effect of, on metabolism of antipsychotic drugs, 231t
- Clanging, in thought disorder, 24t
- Classification of conventional medications, 116
- Clinical Antipsychotic Trials for Interventions Effectiveness (CATIE)  
 antipsychotic medication change in, 179  
 economic comparisons in, 246  
 extrapyramidal side effects in, 98  
 extrapyramidal symptoms in, 94  
 in evaluation of antipsychotic medications, 94  
 incidence of type 2 diabetes in, 158  
 lipid changes in, 163  
 on clozapine in treatment-resistant schizophrenia, 201  
 on comparative efficacy and tolerability in SGADs, 93  
 sexual dysfunction in, 108  
 weight changes in, 149, 153, 153t
- Clinical Global Impression (CGI), in assessment of treatment response, 43
- Clinical presentation, 20-26
- Clonidine, in hypersalivation, 68t
- Clozapine  
 adverse effects of, 65-71, 66-67t  
 as first-line therapy, by comorbidity, 40-41t  
 benefit of, in risk for suicide, 174  
 chemical structure of, 55  
 clinical trials in, 59  
 comparative incidence of extrapyramidal side effects in, 98, 102, 104  
 comparative sexual function with, 106  
 comparative side effects of, 98, 99t, 100t  
 diabetic ketoacidosis in, 161  
 dopamine receptor affinity of, 101  
 dosing information for, 56-57t, 63, 63t  
 drug interactions with, 230, 232t  
 effect on cognition by, 237  
 efficacy, 62  
 history, 61-62

- Clozapine (*continued*)
- in adolescents and children with schizophrenia, 214, 215-216
  - incidence of type 2 diabetes with, 157
    - increased risk for, 159, 161, 162
    - mechanism for, 158
  - in combination therapy for treatment-resistant schizophrenia, 206, 207t
  - in schizoaffective disorder, 222, 223
  - in schizophrenia with depression, 223
  - in schizophrenia with substance abuse, 221
  - in SGAD therapy, 37t
  - in the elderly, 218, 219, 220
  - in therapy for treatment-resistant schizophrenia, 62, 198, 199, 200, 201, 202-203t
  - in treatment algorithm, 38
  - in treatment of aggressive behavior, 173
  - in treatment-resistant schizophrenia, 197
  - introduction of, 34
  - lipid changes with, 163, 165
  - mechanism of action, 62
  - metabolic syndrome with, 146
  - metabolism of, 230t
  - pharmacokinetics, 64
  - potential benefits of new forms of, 182
  - potential cost benefits of, 246
  - profiles for receptor binding, 54
  - rebound phenomenon with, 63
  - receptor affinity of, 95t
  - serotonin selectivity of, 19
  - vs chlorpromazine, in Kane, 62
  - vs risperidone in treatment-resistant schizophrenia, 201
  - weight gain with, 149, 150, 151
- Clozaril. See also *Clozapine*.
- adverse effects of, 65-71, 66-67t
  - clinical trials in, 59
  - dosing information for, 56-57t, 63, 63t
  - efficacy, 62
  - history, 61-62
  - in SGAD therapy, 37t
  - in therapy for treatment-resistant schizophrenia, 198
  - mechanism of action, 62
  - pharmacokinetics, 64
  - rebound phenomenon with, 63
- CNS. See *Central nervous system*.
- Cocaine
- abuse, with schizophrenia, 220-222
  - association with aggressive behavior, 172t
  - positive psychotic symptoms with, 16
- Cognitive behavior therapy (CBT)
- in combination therapy for treatment-resistant schizophrenia, 208
  - in psychosocial rehabilitation, 42
- Cognitive deficit, with schizophrenia, 235
- Cognitive disturbance, in treatment with conventional antipsychotics, 125
- Cognitive remediation (CR), in psychosocial rehabilitation, 42
- Cognitive symptoms, 13, 22, 23t
- Combination therapy
- in the elderly, 217-220
  - in treatment-resistant schizophrenia, 205-208
- Comparison of Atypicals for First-Episode Psychosis (CAFE) study, 97
- Compliance, as factors in relapse, 241
- Conceptual disorganization, in assessment of psychopathology, 44t
- Concreteness, in thought disorder, 24t
- Confusion, with clozapine, 66t
- Congenital long QT syndrome, in predisposition to QTc prolongation, 110
- Constipation
- comparative incidence of, in SGAD therapy, 99t
  - with aripiprazole, 61t
  - with clozapine, 66t
  - with long-acting risperidone, 193-194
  - with olanzapine therapy, 74-75t
  - with quetiapine, 80t
  - with risperidone, 84t
  - with ziprasidone, 88t
- Consumption of a large meal, in predisposition to QTc prolongation, 110
- Conventional therapy. See also *specific drugs*.
- adverse effects of, 121-132
  - available agents for, 36t
  - chemical structure of, 115, 118-119
  - depot preparations of, 190-191, 191t
  - effect on cognition by, 237
  - efficacy and dosing, 116-117, 120-121t
  - history of, 115
  - in adolescents and children with schizophrenia, 214
  - incidence of extrapyramidal effects with, vs SGAD therapy, 98, 102
  - increased risk of suicide with, 174
  - limitations of, 33
  - mechanisms of action, 115
  - overview of, 34-35
  - pharmacokinetics, 117
  - vs SGAD therapy in treatment adherence, 242-243
  - vs SGADs in treatment adherence, 242-243
  - vs SGADs, 34
- Cortical atrophy
- in schizophrenia, 15t
  - in treatment-resistant schizophrenia, 199
- Cost-effectiveness. See also *Economics*.
- of SGADs vs conventional therapy, 35
- Cough
- with aripiprazole, 61t
  - with olanzapine therapy, 74-75t
  - with risperidone, 84t
  - with ziprasidone, 88t

CR. See *Cognitive remediation*.

Creatine phosphokinase, in Levenson's diagnostic criteria for NMS, 131t

Cyproheptadine, in treatment of sexual disturbance in antipsychotic therapy, 109t

D-amino-acid-oxidase activator, in vulnerability for schizophrenia, 21t

DAO, in vulnerability for schizophrenia, 21t

DAOA, in vulnerability for schizophrenia, 21t

Deafness, in diagnosis of psychotic disorder, 30t

Deficit syndrome, 21, 25, 25t

Definition of schizophrenia, 20

Delirium, in diagnosis of psychotic disorder, 30t

Delusions

- in differential diagnosis, 28t
- in symptomatology of schizophrenia, 13
- of influence, 23t
- types of, 22, 23t
- with functional brain changes, 16t

Demence précoce, in historical description of mental illness, 14

Dementia

- in diagnosis of psychotic disorder, 30t
- treatment of, with antipsychotic drugs, 33

Dementia praecox, in historical description of mental illness, 14, 222

Depersonalization, defined, 23t

Depression

- in assessment of psychopathology, 45t
- treatment of, with antipsychotic drugs, 33
- with schizophrenia, SGAD therapy in, 222-223

Derealization, defined, 23t

Dermatologic effects, of conventional psychotic therapy, 127

Desmopressin, in clozapine therapy, 71

Diabeta. See *Glyburide*.

- antidiabetic mechanism of, 164-165t

Diabetes

- classification of, 157-158, 158t
- management of, 162, 164-165t
- mechanism of action, 158, 160
- risk of, in schizophrenia, 156
- in untreated patients, 159-161
- treatment considerations in, 40-41t

Diabetic ketoacidosis

- with antipsychotic drugs, 161
- management of, 162-163

*Diagnostic and Statistical Manual of Mental Disorders*, 4th edition

- definition of schizophrenia in, 26
- rating scales used by, 48

Diagnostic criteria, 26-27, 28-29

Diarrhea

- with clozapine, 67t
- with ziprasidone, 88t

Diazepam, for acute agitation, 168

Dibenzodiazepines, as subclass of antipsychotic medication, 116, 118-119

Dibenzoxazepines, chemical structure of, 118-119

Diencephalic gliosis, associated abnormalities of, in schizophrenia, 15t

Dihydroergotamine, with clozapine therapy, 69

Dihydroindolones

- as subclass of antipsychotic medication, 116, 118-119
- chemical structure of, 118-119

Diltiazem, effect of, on metabolism of antipsychotic drugs, 231t

Diphenylbutylpiperidines

- as subclass of antipsychotic medication, 116, 118-119
- chemical structure of, 118-119

DISC1, in vulnerability for schizophrenia, 21t

Disorganized behavior

- in differential diagnosis, 28t
- in symptomatology of schizophrenia, 13

Disorganized speech

- in differential diagnosis, 28t
- in symptomatology of schizophrenia, 13

Disorganized type, in categorization of schizophrenia, 26

Disorientation

- in assessment of psychopathology, 47t
- in treatment with conventional antipsychotics, 125

Dizziness

- comparative incidence of, in SGAD therapy, 99t
- with clozapine, 66t
- with olanzapine therapy, 74-75t
- with paliperidone ER, 78t
- with quetiapine, 80t
- with ziprasidone, 88t

Docusate, in treatment of anticholinergic effects of conventional antipsychotics, 125

Dofetilide, contraindicated with ziprasidone, 89

Dopamine receptor antagonism

- adverse effects of, 122t
- effect of, on satiety, 148
- in conventional therapy, 115
- in mechanism of action, conventional therapy, 53
- in sexual dysfunction, 106t

Dopamine transmission, role of, in schizophrenia, 19

Dopamine transmitter system, dysfunction of, in schizophrenia, 18

Dopaminergic hyperactivity, impact on glucose metabolism, 18

Dopaminergic hypoactivity, impact on glucose metabolism, 18

Dopaminergic receptor-deficit hypothesis, 18-19, 249

Dopaminergic system, in etiology of schizophrenia, 16-19, 17, 18t

Droperidol, contraindicated with ziprasidone, 232

Drowsiness, with clozapine, 66t

Drug absorption, factors affecting, 227-228

Drug interactions, 227-233

Drug intoxication, in diagnosis of psychotic disorder, 30t

- Dry mouth  
 comparative incidence of, in SGAD therapy, 99t  
 with clozapine, 66t  
 with long-acting risperidone, 193-194  
 with olanzapine therapy, 74-75t  
 with quetiapine, 80t  
 with ziprasidone, 88t
- Dry skin, with risperidone, 84t
- D-serine, potential benefits of, in schizophrenia, 239
- DTNBP1, in vulnerability for schizophrenia, 21t
- Duration of symptoms, in differential diagnosis, 28t
- Duration of untreated psychosis, impact on prognosis, 96
- Dysbindin, in vulnerability for schizophrenia, 21t
- Dyspepsia  
 comparative incidence of, in SGAD therapy, 99t  
 with aripiprazole, 61t  
 with long-acting risperidone, 193-194  
 with olanzapine therapy, 74-75t  
 with paliperidone ER, 78t  
 with quetiapine, 80t  
 with risperidone, 84t  
 with ziprasidone, 88t
- Early-onset schizophrenia, 213
- Echymosis, with olanzapine therapy, 74-75t
- Echolalia, in thought disorder, 24t
- Economics, impact of schizophrenia on, 244-245, 245t
- Elderly patients, antipsychotic treatment of, 216-220
- Electroconvulsive therapy, in treatment-resistant schizophrenia, 205
- Electrolyte imbalance, in diagnosis of psychotic disorder, 30t
- Emotional withdrawal, in assessment of psychopathology, 44t
- Employment, issues in schizophrenia, 243
- Endocrine disturbances  
 in diagnosis of psychotic disorder, 30t  
 with antipsychotic therapy, 129
- Enuresis, in antipsychotic-treated children, 215
- Ephedrine, in clozapine therapy, 71
- Epidemiologic Catchment Area Study, schizophrenia in the elderly in, 216-217
- Epidemiology, 13-14, 14t
- Epilepsy, in diagnosis of psychotic disorder, 30t
- Epileptogenic effects, with antipsychotic therapy, 128
- Ergotomatic delusions, defined, 23t
- Erythromycin, effect of, on metabolism of antipsychotic drugs, 231t
- Etiology of schizophrenia, 16
- Excitement, in assessment of psychopathology, 47t
- Executive function, in schizophrenia, 235
- Extrapyramidal pathway, role in effect of antipsychotic drugs, 16, 17
- Extrapyramidal symptoms  
 comparative incidence of, in SGAD therapy, 99t, 100t
- Extrapyramidal symptoms (*continued*)  
 in CATIE trial, 94  
 in schizophrenia with substance abuse, 220-222  
 in sexual dysfunction, 106t  
 noncompliance due to, 242  
 SGAD vs conventional therapy in children, 215  
 susceptibility to, of elderly patients, 218  
 treatment considerations in, 40-41t  
 with haloperidol therapy, 168  
 with paliperidone ER, 77, 78t  
 with risperidone, 84t  
 with SGAD vs conventional therapy, 98  
 with ziprasidone, 88t
- Extremity pain, with olanzapine therapy, 74-75t
- Family education, in psychosocial rehabilitation, 42
- Farampator  
 in new developments for treating schizophrenia, 251  
 potential benefits of, in schizophrenia, 239
- Fatigue  
 with clozapine, 67t  
 with hepatic changes in antipsychotic therapy, 128  
 with long-acting risperidone, 193-194
- Fazaclo. See also *Clozapine*.  
 in SGAD therapy, 37t
- FDA. See *Food and Drug Administration*.
- Female gender, in predisposition to QTc prolongation, 110
- Fenfluramine, use of, in patients on antipsychotic drugs, 155
- Fever  
 comparative incidence of, in SGAD therapy, 99t  
 in Levenson's diagnostic criteria for NMS, 131t  
 in treatment with conventional antipsychotics, 125  
 with clozapine, 66t  
 with hepatic changes in antipsychotic therapy, 128  
 with olanzapine therapy, 74-75t  
 with quetiapine, 80t  
 with risperidone, 84t
- FGA. See *First-generation antipsychotic (drug)*.
- First-generation antipsychotic drug. See also *Conventional therapy*.  
 in treatment algorithm, 38  
 vs second-generation agents, 96-97
- Fluency, in schizophrenia, 235
- Fluid imbalance, in diagnosis of psychotic disorder, 30t
- Fluoroquinolones, effect of, on metabolism of antipsychotic drugs, 231t
- Fluoxetine  
 effect of, on metabolism of antipsychotic drugs, 231t  
 in schizoaffective disorder, 223  
 in schizophrenia with depression, 223
- Fluphenazine  
 adverse effects with, 123t

- Fluphenazine (*continued*)  
 chemical structure of, 118-119  
 depot preparations of, 119-120  
 dopamine receptor affinity of, 101  
 dosing guidelines for, 120-121t  
 for long-acting antipsychotic therapy, 190, 191t  
 in conventional antipsychotic therapy, 36t  
 in treatment algorithm, 38  
 introduced for antipsychotic use, 33  
 metabolism, 229-233  
 relapse with, 242  
 vs risperidone in treatment-resistant schizophrenia, 201  
 weight gain with, 151
- Fluvoxamine  
 effect of, on metabolism of antipsychotic drugs, 231t  
 in combination therapy for treatment-resistant schizophrenia, 207t  
 in schizoaffective disorder, 223  
 in schizophrenia with depression, 223
- fMRI. See *Functional magnetic resonance imaging*.
- Food and Drug Administration (FDA)  
 guidelines for clozapine (Clozaril) in resistant disease, 198, 202-203t  
 recommendations for clozapine administration, 65
- Frontal cortex, role of, in dopaminergic receptor-deficit hypothesis, 18
- Functional abnormalities, 15, 15t, 16t
- Functional magnetic resonance imaging (fMRI), in characterization of  
 brain abnormality, 14
- Fungal dermatitis, with ziprasidone, 88
- Future direction of therapy, 249-252
- Galactorrhea, with risperidone, 107
- Galantamine, potential benefits of, in schizophrenia, 239
- GAF. See *Global Assessment of Function scale*.
- GAS. See *Global Assessment Scale*.
- Gastrointestinal disturbance, with hepatic changes in antipsychotic  
 therapy, 128
- Gatifloxacin, contraindicated with ziprasidone, 232
- Genes involved in schizophrenia, 20-21
- Genetic polymorphism, interaction of, with antipsychotic therapy, 236
- Genetic predisposition, potential role in psychotic disease, 19-20, 20-21t
- Geodon. See also *Ziprasidone*.  
 adverse effects, 87-90, 88t  
 dosing information for, 56-57t  
 efficacy, 86-87  
 history, 86  
 in management of acute psychosis, 170-171t  
 in SGAD therapy, 37  
 mechanism of action, 86  
 pharmacokinetics, 87
- Geriatrics. See *Elderly patients*.
- Glaucoma, with conventional antipsychotic therapy, 126
- Glimepiride (Amaryl), antidiabetic mechanism of, 164-165t
- Glipizide (Glucotrol), antidiabetic mechanism of, 164-165t
- Global Assessment of Function (GAF) scale, vs GAS in evaluation of  
 function, 48
- Global Assessment Scale (GAS)  
 example of, 50-51t  
 in evaluation of function, 48
- Glucophage. See *Metformin*.  
 antidiabetic mechanism of, 164-165t
- Glucophage XR. See *Metformin*.  
 antidiabetic mechanism of, 164-165t
- Glucose dysregulation, in psychotic patients, 156-163
- Glucose metabolism  
 comparative changes of, in SGADs, 100t  
 role of, in dopaminergic receptor-deficit hypothesis, 18
- Glucotrol. See *Glipizide*  
 antidiabetic mechanism of, 164-165t.
- Glucovance. See *Glyburide and metformin*.  
 antidiabetic mechanism of, 164-165t
- Glutamate release, role of, in schizophrenia, 19
- Glutamate subtype receptor, role of, in schizophrenia, 18-19
- Glutamate transmitter system, dysfunction of, in schizophrenia, 18
- Glutamatergic transmission, role in cognitive processes, 238
- Glyburide (Diabeta), antidiabetic mechanism of, 164-165t
- Glyburide and metformin (Glucovance), antidiabetic mechanism of,  
 164-165t
- Glycine, potential benefits of, in schizophrenia, 239
- Glycopyrrolate, in hypersalivation, 68t
- Glyset. See *Miglitol*.  
 antidiabetic mechanism of, 164-165t
- Grandiose delusions, defined, 23t  
 in assessment of psychopathology, 45
- Grapefruit, effect of, on metabolism of antipsychotic drugs, 231t
- Guilt feelings, in assessment of psychopathology, 45t
- Gynecomastia, with risperidone, 107
- Haldol. See also *Haloperidol*.  
 in conventional antipsychotic therapy, 36t
- Hallucinations  
 in assessment of psychopathology, 46t  
 in differential diagnosis, 28t  
 in symptomatology of schizophrenia, 13, 22  
 in treatment with conventional antipsychotics, 125
- Halofantrine, contraindicated with ziprasidone, 232
- Haloperidol  
 adverse effects with, 123t  
 chemical structure of, 118-119  
 chemical structure of, 55  
 comparative incidence of extrapyramidal side effects in, 98, 102, 104  
 depot preparations of, 119-120

## Haloperidol (*continued*)

- dopamine receptor affinity of, 101
  - dosing guidelines for, 120-121t
  - effect of, on metabolism of antipsychotic drugs, 231t
  - effect of, on QTc interval, 111
  - effect on cognition by, 237
  - extrapyramidal symptoms in, 168
    - for acute agitation, 168
    - for long-acting antipsychotic therapy, 190, 191t
  - in adolescents and children with schizophrenia, 214
  - in CATIE trial, 94
  - in conventional antipsychotic therapy, 36t
  - in long-term maintenance therapy, 178
  - in pregnancy/lactation, 225
  - in schizophrenia with substance abuse, 221
  - in treatment algorithm, 38
  - in treatment of aggressive behavior, 173
  - introduced for antipsychotic use, 33
  - metabolism of, 229-233, 230t
    - of SGADs, 95t
    - potential cost benefits of, 246
    - profiles for receptor binding, 54
    - remission rates with, 185
    - surgically implantable, long-acting, preclinical studies of, 195
    - vs olanzapine, 72
    - vs risperidone in prevention of relapse, 178
    - vs risperidone in treatment-resistant schizophrenia, 201
    - vs ziprasidone, 87
  - weight gain with, 150, 151
- ## Headache
- comparative incidence of, in SGAD therapy, 99t
    - with aripiprazole, 61t
    - with clozapine, 66t
    - with paliperidone ER, 78t
    - with quetiapine, 80t
    - with risperidone, 84t
- ## Heart failure, in predisposition to QTc prolongation, 110
- ## Hecker, in early characterization of mental illness, 14
- ## Hematologic side effects
- of clozapine, 65
  - of conventional psychotic therapy, 126
- ## Hepatic disease, in diagnosis of psychotic disorder, 30t
- ## Hepatic effects, of conventional psychotic therapy, 127
- ## Hepatic metabolism
- of paliperidone ER, 76
  - of risperidone, 83
- ## Hippocampus
- impact of functional changes in, 16t
  - role in effect of antipsychotic drugs, 16, 17

## Histamine receptor

- adverse effects with antagonism of, 122t
  - influence of, in weight gain, 140, 150
- ## Historical perspective, 13
- ## Homovanillic acid (HVA), role of, in dopaminergic receptor-deficit hypothesis, 18
- ## Hostility
- in assessment of psychopathology, 46t
  - in symptomatology of schizophrenia, 25
- ## Huntington's chorea, in diagnosis of psychotic disorder, 30t
- ## HVA. See *Homovanillic acid*.
- ## Hypercapnia, in diagnosis of psychotic disorder, 30t
- ## Hyperglycemia, in predisposition to QTc prolongation, 110
- ## Hyperkinesia, with paliperidone ER, 78t
- ## Hyperlipidemia
- in schizophrenic patients, 163
  - management of, 163, 165
  - treatment considerations in, 40-41t
  - with antipsychotic therapy, 163
- ## Hypersalivation
- in antipsychotic-treated children, 215
  - with clozapine, 68
  - treatments for, 68t
- ## Hypertension
- with clozapine, 66t
  - with olanzapine therapy, 74-75t
- ## Hyperthyroidism, in diagnosis of psychotic disorder, 30t
- ## Hypertonia, with olanzapine therapy, 74-75t
- ## Hypertriglyceridemia, treatment considerations in, 40-41t
- ## Hypnagogic hallucinations, in diagnosis of psychotic disorder, 30t
- ## Hypnopompic hallucinations, in diagnosis of psychotic disorder, 30t
- ## Hypoadrenocorticism, in diagnosis of psychotic disorder, 30t
- ## Hypocalcemia, in predisposition to QTc prolongation, 110
- ## Hypoglycemia, in diagnosis of psychotic disorder, 30t
- ## Hypokalemia, in predisposition to QTc prolongation, 110
- ## Hypokinesia, with clozapine, 66t
- ## Hypomagnesemia, in predisposition to QTc prolongation, 110
- ## Hypotension
- comparative incidence of, in SGAD therapy, 99t
  - with clozapine, 66t
- ## Hypothalamus, role in effect of antipsychotic drugs, 16, 17
- ## Hypothyroidism
- in diagnosis of psychotic disorder, 30t
  - in predisposition to QTc prolongation, 110
  - with quetiapine, 79
- ## Hypoxia, in diagnosis of psychotic disorder, 30t
- 
- ## Ideas of reference, defined, 23t
- ## Iloperidone, in new developments for treating schizophrenia, 250
- ## Increased appetite, with olanzapine therapy, 74-75t

- Insomnia  
 in rebound phenomenon, 63  
 with aripiprazole, 61t  
 with clozapine, 67t  
 with olanzapine therapy, 74-75t  
 with paliperidone ER, 78t  
 with risperidone, 84t
- Invega. See also *Paliperidone ER*.  
 adverse effects, 77, 78t  
 dosing, 76  
 efficacy, 75-76  
 history, 75  
 in SGAD therapy, 37t  
 mechanism of action, 75  
 pharmacokinetics, 76
- Itraconazole, effect of, on metabolism of antipsychotic drugs, 231t
- Jervell and Lange-Nielsen syndrome, in predisposition to QTc prolongation, 110
- Joint pain, with olanzapine therapy, 74-75t
- Kahlbaum, in early characterization of mental illness, 14
- Ketamine  
 role of, in modeling schizophrenia, 18  
 potential benefits of, in schizophrenia, 239
- Ketoconazole, effect of, on metabolism of antipsychotic drugs, 231t
- Kraepelin  
 characterization of schizophrenia by, 21, 222  
 in early characterization of mental illness, 14
- Kussmaul's respiration, 161
- Lack of insight, defined, 23t
- Lactation, management of schizophrenia during, 224-225
- Lamotrigine, in combination therapy for treatment-resistant schizophrenia, 207t
- Leukopenia, with clozapine, 66t
- Lightheadedness, with aripiprazole, 61t
- Lipid abnormalities, comparative incidence of, in SGADs, 100t
- Lithium  
 effect on drug absorption, 228  
 in renal impairment, 233  
 in schizoaffective disorder, 223  
 in schizophrenia with depression, 223
- Liver disease, in predisposition to QTc prolongation, 110
- Long-acting antipsychotic drug therapy  
 benefits and disadvantages of, 189-190  
 SGAD vs conventional, 189, 190-191
- Long-term outcome, 241-243
- Loose association, in thought disorder, 24t
- Lorazepam, for acute agitation, 168
- Low-energy diets, in predisposition to QTc prolongation, 110
- Loxapine  
 adverse effects with, 123t  
 chemical structure of, 118-119  
 dopamine receptor affinity of, 101  
 dosing guidelines for, 120-121t  
 in conventional antipsychotic therapy, 36t
- Loxitane. See also *Loxipine*.  
 in conventional antipsychotic therapy, 36t
- LSD. See *Lysergic acid diethylamide*.
- Lurasidone, in new developments for treating schizophrenia, 251
- Lysergic acid diethylamide (LSD), role of, in generation of serotonin hypothesis of psychosis, 19
- Maintenance therapy, recommendations for, 177
- Major depression, in diagnosis of psychotic disorder, 30t
- Malaise  
 in rebound phenomenon, 63  
 with hepatic changes in antipsychotic therapy, 128
- Manic depressive psychosis, Kraepelin description of, 222
- Mannerisms, in assessment of psychopathology, 45t
- Marijuana. See *Cannabis*.
- MATRICES project, consensus building in, 236
- Medical disorder, exclusion of, in diagnosis of schizophrenia, 29t
- Mefloquine, contraindicated with ziprasidone, 232
- Meglitinides, antidiabetic mechanism of, 164-165t
- Mellaril. See also *Thioridazine*.  
 in conventional antipsychotic therapy, 36t
- Memory, in schizophrenia, 235
- Menstrual irregularities  
 with conventional antipsychotic therapy, 103  
 with olanzapine, 107  
 with risperidone, 107
- Meridia. See *Sibutramine*.
- Mesocortical  
 effect of antipsychotic drugs on, 18  
 role in effect of antipsychotic drugs, 16, 17
- Mesolimbic pathway  
 effect of antipsychotic drugs on, 18  
 role in effect of antipsychotic drugs, 16, 17
- Mesoridazine  
 adverse effects with, 123t  
 anticholinergic effects of, 125  
 chemical structure of, 118-119  
 contraindicated with ziprasidone, 232  
 dosing guidelines for, 120-121t  
 effect on cognition by, 237  
 in conventional antipsychotic therapy, 36t  
 weight gain with, 151
- Metabolic abnormalities, in predisposition to QTc prolongation, 110

Metabolic conditions, in diagnosis of psychotic disorder, 30t

Metabolic syndrome

- cardiovascular disease in, 145, 146t
- in schizophrenic patients, 146
- in treatment of anticholinergic effects of conventional antipsychotics, 125

Metamucil

- NCEP definition of, 145,
- role of antipsychotic medications in, 46

Metformin (Glucophage, Glucophage XR), antidiabetic mechanism of, 164-165t

Midriasis, in treatment with conventional antipsychotics, 125

Mifepristone, in new developments for treating schizophrenia, 250

Miglitol (Glyset), antidiabetic mechanism of, 164-165t

Migraine, in diagnosis of psychotic disorder, 30t

Mitral valve prolapse, in predisposition to QTc prolongation, 110

Moban. See also *Molindone*.

- in conventional antipsychotic therapy, 36t

Molindone, weight gain with, 151

- adverse effects with, 123t
- chemical structure of, 118-119
- dopamine receptor affinity of, 101
- dosing guidelines for, 120-121t
- in conventional antipsychotic therapy, 36t

Mood disorder

- exclusion of, in diagnosis of schizophrenia, 29t
- with schizophrenia, treatment of, 222-224

Morel, in early characterization of mental illness, 14

Motor retardation, in assessment of psychopathology, 47t

Movement, effect of antipsychotic drugs on, 18

Moxifloxacin, contraindicated with ziprasidone, 89, 232

Muscarinic receptor, adverse effects with antagonism of, 122t

Myalgia, with hepatic changes in antipsychotic therapy, 128

Myocardial infarction, in predisposition to QTc prolongation, 110

Myocardial ischemia, in predisposition to QTc prolongation, 110

Myocarditis, in predisposition to QTc prolongation, 110

Myoclonus, as warning sign in clozapine therapy, 70

Nateglinide (Starlix), antidiabetic mechanism of, 164-165t

National Cholesterol Education Program, definition of metabolic syndrome, 145, 46t

National Institutes of Mental Health

- MATRICES project of, 236
- recommendations on clozapine therapy, 63

Nausea

- comparative incidence of, in SGAD therapy, 99t
- in rebound phenomenon, 63
- with aripiprazole, 61t
- with clozapine, 66t
- with risperidone, 84t
- with ziprasidone, 88t

Navane. See also *Thiothixene*.

- in conventional antipsychotic therapy, 36t

NCEP. See *National Cholesterol Education Program*.

Nefazodone, effect of, on metabolism of antipsychotic drugs, 231t

Negative symptoms

- characterization of, 22, 25, 25t
- effect of antipsychotic drugs on, 18
- in differential diagnosis, 28t
- with functional brain changes, 16t

Neologism, in thought disorder, 24t

Neoplasm, in diagnosis of psychotic disorder, 30t

Neuregulin, in vulnerability for schizophrenia, 21t

Neuroadrenoline antagonism, effect of, on satiety, 148

Neurocognition

- deficits in schizophrenia, 235
- importance of, in treatment outcome, 236
- susceptibility to, of elderly patients, 218

Neuroleptic agents. See *Conventional therapy*.

Neuroleptic Malignant Syndrome (NMS), 130-132, 131t, 132t

Neurologic conditions, in diagnosis of psychotic disorder, 30t

Nigrostriatal tract

- effect of antipsychotic drugs on, 18
- role in effect of antipsychotic drugs, 16, 17

Nizatadine, use of, in patients on antipsychotic drugs, 155

*N*-methyl-D-aspartate (NMDA), role of, in schizophrenia, 18-19

NMS. See *Neuroleptic Malignant Syndrome*.

Nonadherence, treatment considerations in, 40-41t

Noncompliance

- adverse effects, as cause of, 182
- contributing factors in, 181, 181t
- improvement of, with SGADs, 182
- new formulations for, 182
- nonpharmacologic methods for improving, 183
- relapse factors in, 241

Nonpharmacologic therapy, 39, 42

- Psychosocial interaction as, 39

NRG1, in vulnerability for schizophrenia, 21t

Nucleus accumbens, role in effect of antipsychotic drugs, 16, 17

Obesity

- in predisposition to QTc prolongation, 110
- treatment considerations in, 40-41t

Olanzapine

- adverse effects of, 73, 74t
- as first-line therapy, by comorbidity, 40-41t
- chemical structure of, 55
- comparative efficacy of, 94-97, 96t
- comparative incidence of extrapyramidal side effects in, 98, 102, 104
- comparative side effects of, 98, 99t, 100t
- diabetic ketoacidosis in, 161

- Olanzapine (*continued*)
- discontinuation rates, in CATIE, 179
  - dopamine receptor affinity of, 101
  - dosing information for, 56-57t, 72
  - drug interactions with, 230, 232t
  - effect of, on QTc interval, 111
  - effect on cognition by, 237
  - efficacy, 71
  - history of, 71
  - in adolescents and children with schizophrenia, 214, 215-216
  - in CAFE study, 97
  - in CATIE trial, 94
  - in combination therapy for treatment-resistant schizophrenia, 207t
  - in first-episode schizophrenia, 97
  - in management of acute psychosis, 170-171t
  - in new developments for treating schizophrenia, 250
  - in schizophrenia with substance abuse, 221
  - in SGAD therapy, 37t
  - in the elderly, 218, 220
  - in therapy for treatment-resistant schizophrenia, 199
  - in treatment algorithm, 38
  - in treatment of aggressive behavior, 173
  - in treatment-resistant schizophrenia, 204
  - lipid changes with, 165
  - long-acting, phase 3 trials of, 195
  - mechanism of action, 71
  - metabolic syndrome with, 146
  - metabolism of, 229-233, 230t
  - pharmacokinetics, 72
  - potential benefits of new forms of, 182
  - profiles for receptor binding, 54
  - receptor affinity of, 95t
  - remission rates with, 185
  - sedative effect, in clinical trials, 112
  - vs clozapine in risk for suicide, 174
  - vs haloperidol, 71-72
  - vs risperidone in prevention of relapse, 178
  - weight gain with, 149, 150, 151, 152t
- Omeprazole, effect of, on metabolism of antipsychotic drugs, 231t
- Onset, in epidemiology of schizophrenia, 13, 14t
- Ophthalmic changes, of conventional psychotic therapy, 126
- Orap. See also *Pimozide*.
- in conventional antipsychotic therapy, 36t
- Orbitofrontal cortex, in treatment-resistant schizophrenia, 199
- Orlistat, use of, in patients on antipsychotic drugs, 155
- OROS technology, with paliperidone ER, 75, 76
- Orthostatic hypotension
- comparative incidence of, in SGADs, 100t
  - in antipsychotic therapy for the elderly, 218
  - with clozapine therapy, 69
  - with conventional therapies, 124
- Overinclusiveness, in thought disorder, 24t
- Paliperidone ER
- adverse effects, 77, 78t
  - as first-line therapy, by co-morbidity, 40-41t
  - chemical structure of, 55
  - comparative incidence of extrapyramidal side effects in, 98, 102, 104
  - comparative side effects of, 98, 99t, 100t
  - dosing, 76
  - efficacy, 75-76
  - history, 75
  - in adolescents and children with schizophrenia, 214
  - in new developments for treating schizophrenia, 250
  - in SGAD therapy, 37t
  - in treatment-resistant schizophrenia, 205
  - in young patients, 97
  - mechanism of action, 75
  - pharmacokinetics, 76
  - sedative effect, in clinical trials, 112
  - studies of, 75-76
  - weight gain with, 152t
- PANSS. See *Positive and Negative Syndrome Scale*.
- Paranoid type, in categorization of schizophrenia, 27
- Parietal cortex
- impact of functional changes in, 16t
  - role in effect of antipsychotic drugs, 16, 17
- Parkinsonian symptoms, in antipsychotic therapy for the elderly, 218
- Parkinson's disease
- in predisposition to QTc prolongation, 110
  - psychosis with, in the elderly, 217
  - SGAD therapy in, 219
  - with long-acting risperidone, 193-194
- Paroxetine
- effect of, on metabolism of antipsychotic drugs, 231t
  - in schizoaffective disorder, 223
  - in schizophrenia with depression, 223
- Pathophysiology, 14-19
- PCP. See *Phencyclidine*.
- Pentamidine, contraindicated with ziprasidone, 232
- Peripheral edema, with olanzapine therapy, 74-75t
- Periventricular nuclei, role in effect of antipsychotic drugs, 16, 17
- Perphenazine
- adverse effects with, 123t
  - chemical structure of, 118-119
  - dosing guidelines for, 120-121t
  - effect of, on metabolism of antipsychotic drugs, 231t
  - in CATIE trial, 94, 153t
  - in conventional antipsychotic therapy, 36t
  - in schizophrenia with substance abuse, 221
  - metabolism of, 229-233, 230t

- Persecutory delusions, defined, 23t
- Perseveration, in thought disorder, 24t
- Personality disorder, comparative incidence of, in SGAD therapy, 99t
- Pervasive developmental disorder
- exclusion of, in diagnosis of schizophrenia, 29t
  - in diagnosis of psychotic disorder, 30t
- PET. See *Positron emission tomography*.
- Pharmacodynamics
- definition of, 227
  - in the elderly, 217-220
- Pharmacokinetics
- definition of, 227
  - in the elderly, 217-220
- Pharyngitis
- with olanzapine therapy, 74-75t
  - with risperidone, 84t
- Phencyclidine (PCP)
- role of, in modeling schizophrenia, 18
  - potential benefits of, in schizophrenia, 239
- Phenobarbital
- association with aggressive behavior, 172t
  - effect of, on metabolism of antipsychotic drugs, 231t
- Phenothiazines
- as subclass of antipsychotic medication, 116, 118-119
  - chemical distinctions among, 115-116, 118-119
  - in pregnancy/lactation, 225
  - lipid changes with, 163, 165
- Phenteramine, use of, in patients on antipsychotic drugs, 155
- Phenylpropanolamine, association with aggressive behavior, 172t
- Phenytoin
- effect of, on metabolism of antipsychotic drugs, 231t
  - in prevention of seizure with clozapine therapy, 70
- Physiologic changes, in responsive vs resistant schizophrenia, 199
- Pimozide
- chemical structure of, 118-119
  - contraindicated with ziprasidone, 89, 232
  - dosing guidelines for, 120-121t
  - in combination therapy for treatment-resistant schizophrenia, 207t
  - in conventional antipsychotic therapy, 36t
- Pioglitazone (Actos), antidiabetic mechanism of, 164-165t
- Piperazines
- chemical structure of, 118-119
  - in phenothiazine subtyping, 115
- Piperidines
- chemical structure of, 118-119
  - in phenothiazine subtyping, 115
- Pituitary, role in effect of antipsychotic drugs, 16, 17
- Polypharmacy, in the elderly, 217-220
- Portal blood system, role in effect of antipsychotic drugs, 16, 17
- Positive and Negative Syndrome Scale (PANSS)
- comparison of SGAD efficacy by, 97
  - in assessment of schizophrenia, 43, 48
  - in evaluation of treatment in children, 216
- Positive symptoms, with functional brain changes, 16t
- Positron emission tomography (PET)
- in characterization of brain abnormality, 14
  - role of, in dopaminergic receptor-deficit hypothesis, 18
- Postural hypotension
- comparative incidence of, in SGAD therapy, 99t
  - with olanzapine therapy, 74-75t
  - with quetiapine, 80t
- Posturing, in assessment of psychopathology, 45t
- Prandin. See *Repaglinide*.
- antidiabetic mechanism of, 164-165t
- Precose. See *Acarbose*.
- Prefrontal cortex
- impact of functional changes in, 16t
  - role in effect of antipsychotic drugs, 16, 17
- Pregnancy, management of schizophrenia during, 224-225
- Prenatal environment, role of, in genesis of psychotic disease, 20
- Prevalence, in epidemiology of schizophrenia, 14t
- Priapism, with risperidone, 107
- Prodromal effects, of conventional antipsychotic therapy, 127
- Prodromal phase, characteristics of, 13
- Prognosis, 27
- factors affecting, 30, 30t, 241-242
  - impact of therapeutic advances on, 39
- Prolactin changes
- comparative incidence of, in SGADs, 100t, 106-107
  - mechanism of, in antipsychotic therapy, 103, 106, 106t
  - with paliperidone ER, 76
  - with risperidone, 83
- Prolactin concentrations, effect of antipsychotic drugs on, 18
- Prolixen. See also *Fluphenazine*.
- in conventional antipsychotic therapy, 36t
- Protease inhibitors, effect of, on metabolism of antipsychotic drugs, 231t
- Pruritus, with hepatic changes in antipsychotic therapy, 128
- Psychiatric emergency
- aggressive behavior in, 172-173
  - management goals of, 167
  - SGADs in, 169-171, 171-172t
  - suicidal behavior in, 173-174, 175t
- Psychomotor symptoms, with functional brain changes, 16t
- Psychopathology, in relapse, 241
- Psychosis
- concept of disease in, 13
  - effect of antipsychotic drugs on, 18
  - historical perspective, 13
- Psychosocial function, in symptomatology of schizophrenia, 13

Psychosocial intervention, as nonpharmacologic therapy, 39, 42  
Psychotic symptoms, 22, 23t  
Psychotomimetic drugs, role of, in modeling schizophrenia, 18  
Putamen, role in effect of antipsychotic drugs, 16, 17

#### Quality of life

factors in schizophrenia, 243  
with SGADs vs conventional therapy, 244

#### Quetiapine

adverse effects, 79-82, 80t  
as first-line therapy, by co-morbidity, 40-41t  
chemical structure of, 55  
comparative efficacy of, 94-97, 96t  
comparative incidence of extrapyramidal side effects in, 98, 102, 104  
comparative side effects of, 98, 99t, 100t  
diabetic ketoacidosis in, 161  
discontinuation rates, in CATIE, 179  
dopamine receptor affinity of, 101  
dosing information for, 56-57t, 78-79  
effect of, on glucose homeostasis, 162  
effect of, on QTc interval, 111  
effect on cognition by, 237  
factors affecting absorption, 228  
history, 77  
in adolescents and children with schizophrenia, 214, 215-216  
in CAFE study, 97  
in CATIE trial, 94, 153t  
in combination therapy for treatment-resistant schizophrenia, 207t  
in first-episode schizophrenia, 97  
in SGAD therapy, 37t  
in the elderly, 218  
in treatment algorithm, 38  
in treatment of aggressive behavior, 173  
in treatment-resistant schizophrenia, 204  
mechanism of action, 77  
metabolism of, 229-233, 230t  
pharmacokinetics, 79  
profiles for receptor binding, 54  
receptor affinity of, 95t  
sedative effect, in clinical trials, 112  
studies of, 77-78  
vs risperidone in treatment-resistant schizophrenia, 201  
weight gain with, 150, 151, 152t

#### Quinidine

contraindicated with ziprasidone, 89, 232  
effect of, on metabolism of antipsychotic drugs, 231t

QTc changes, comparative incidence of, in SGADs, 100t

Raclopride, role of, in dopaminergic receptor-deficit hypothesis, 18

#### Rash

comparative incidence of, in SGAD therapy, 99t  
with clozapine, 67t  
with quetiapine, 80t  
with risperidone, 84t  
with ziprasidone, 88t

Rating scales, 42-48, 44-47t

Receptor affinities, of SGADs, 95t

Receptor antagonism, associated adverse effects of, 122t

Receptor-binding profile, of quetiapine, 93

#### Relapse

factors in, 241  
rates, 241

Relationships, as factor in relapse, 241

#### Remission

Schizophrenic Working Group consensus on, 184, 185-186t  
SGAD vs conventional therapy for, 185

Renal disease, in diagnosis of psychotic disorder, 30t

Renal insufficiency, in predisposition to QTc prolongation, 110

#### Renal metabolism

excretion by, 233  
of paliperidone ER, 76

Repaglinide (Prandin), antidiabetic mechanism of, 164-165t

Residual type, in categorization of schizophrenia, 27

#### Respiratory tract infection

comparative incidence of, in SGAD therapy, 99t  
with ziprasidone, 88t

#### Restlessness

in rebound phenomenon, 63  
with clozapine, 66t

RGS4, in vulnerability for schizophrenia, 21t

Rheumatic fever, in predisposition to QTc prolongation, 110

#### Rhinitis

comparative incidence of, in SGAD therapy, 99t  
with aripiprazole, 61t  
with olanzapine therapy, 74-75t  
with quetiapine, 80t  
with risperidone, 84t  
with ziprasidone, 88t

Rifampin, effect of, on metabolism of antipsychotic drugs, 231t

#### Rigidity

in Levenson's diagnostic criteria for NMS, 131t  
with clozapine, 67t

Rimonabant, use of, in patients on antipsychotic drugs, 156

Risk factors, for development of schizophrenia, 20

Risperdal. See also *Risperidone*.

adverse effects, 83-86, 84t  
dosing information for, 56-57t, 82-83  
history, 82

### Risperdal (*continued*)

- in management of acute psychosis, 170-171t
  - in SGAD therapy, 37t
  - long-acting
    - adverse effects of, 193-194
    - dosing guidelines for, 193
    - pharmacology and pharmacokinetics of long-acting preparations of, 191
    - preparation and use of, 194t
    - studies of, 195
  - mechanism of action, 82
  - pharmacokinetics, 83
- ### Risperidone
- adverse effects, 83-86, 84t
  - as first-line therapy, by co-morbidity, 40-41t
  - as first-line therapy in elderly patients, 218
  - with Parkinson's disease, Alzheimer's disease, 219
  - chemical structure of, 55
  - comparative efficacy of, 94-97, 96t
  - comparative incidence of extrapyramidal side effects in, 98, 102, 104
  - comparative side effects of, 98, 99t, 100t
  - diabetic ketoacidosis in, 161
  - discontinuation rates, in CATIE, 179
  - dopamine receptor affinity of, 101
  - dosing information for, 56-57t, 82-83
  - effect of, on glucose homeostasis, 162
  - effect of, on QTc interval, 111
  - effect on cognition by, 237
  - FDA approval of, in prevention of relapse, 178
  - history, 82
  - in adolescents and children with schizophrenia, 214
  - in CAFE study, 97
  - in CATIE trial, 94
  - in combination therapy for treatment-resistant schizophrenia, 206, 207t
  - in first-episode schizophrenia, 97
  - in management of acute psychosis, 170-171t
  - in pregnancy/lactation, 225
  - in schizophrenia with substance abuse, 221
  - in SGAD therapy, 37t
  - in treatment algorithm, 38
  - in treatment of aggressive behavior, 173
  - in treatment-resistant schizophrenia, 201, 204
  - vs haloperidol, 201
  - lipid changes with, 165
  - long-acting
    - adverse effects of, 193
    - dosing guidelines for, 193
    - pharmacology and pharmacokinetics of long-acting preparations of, 191
    - potential benefits of in young patients, 214, 215-216

### Risperidone, long-acting (*continued*)

- preparation and use of, 194t
  - studies of, 195
  - mechanism of action, 82
  - metabolism of, 229-233, 230t
  - pharmacokinetics, 83
  - potential benefits of new forms of, 182
  - potential cost benefits of, 246
  - profiles for receptor binding, 54
  - receptor affinity of, 95t
  - relapse with, vs conventional therapy, 242
  - remission rates with, 185
  - sedative effect, in clinical trials, 112
  - studies of, 82
  - vs haloperidol, 82
  - Marder and Meibach, US-Canada joint, 82
  - weight gain with, 150, 151, 152t
  - in CATIE trial, 153t
- ### Rivastigmine, potential benefits of, in schizophrenia, 239
- ### Romano-Ward syndrome, in predisposition to QTc prolongation, 110
- ### Rosiglitazone (Avandia), antidiabetic mechanism of, 164-165t
- ### Salivation
- with clozapine, 66t
  - with risperidone, 84t
- ### SAS See *Simpson-Angus Scale*.
- ### Schizoaffective disorder
- exclusion of, in diagnosis of schizophrenia, 29t
  - in diagnosis of psychotic disorder, 30t
  - SGAD therapy in, 222-223
  - treatment of, with antipsychotic drugs, 33
- ### Schizophrenia
- defined, *Diagnostic and Statistical Manual of Mental Disorders*, 4th edition, 26
  - treatment of, with antipsychotic drugs, 33
- ### Schizophrenic Working Group, consensus on remission, 184, 185-186t
- ### Second-generation antipsychotic drugs (SGADs). See also specific drugs.
- available agents for, 37t
  - chemical structure of, 55
  - comparative side effects of, 98, 99t
  - depot preparations of, 191-195
  - distinction vs conventional therapy, 34, 96-97
  - dosing information for, 56-57t
  - effect of receptor affinity with weight gain in, 149
  - effect on cognition by, 237
  - factors affecting absorption, 227-228
  - future directions in, 249
  - in adolescents and children with schizophrenia, 214
  - in management of acute psychosis, 170-171t
  - in management of aggressive behavior, 172-173

## SGADs (*continued*)

- in pregnancy/lactation, 225
- in prevention of relapse, 178
- in schizoaffective disorder, 222
- in the elderly, 217-220
- in therapy for treatment-resistant schizophrenia, 198, 199, 200-208
- in treatment algorithm, 38
- incidence of extrapyramidal effects with, vs conventional therapy, 98, 102
- introduced for antipsychotic use, 33-34
- mechanism of action, 53
- metabolism and distribution of, 229-233, 230t
- potential benefits of, 31
- profiles for receptor binding, 54
- risk of diabetes with, 159
- serotonin-to-dopamine binding ratios of, 19
- vs conventional therapy in treatment adherence, 242-243
- vs conventional treatment of psychiatric emergencies, 168

## Sedation

- by receptor antagonism, 122, 122t
- comparative incidence of, in SGAD therapy, 99t
- comparative incidence of, in SGADs, 100t
- comparative, with conventional antipsychotic therapy, 122, 123t
- in CATIE trial, 112
- in sexual dysfunction, 106t
- with clozapine, 67, 67t

## Seizures

- comparative incidence of, in SGADs, 100t
- in treatment with conventional antipsychotics, 125
- preventative measures for, 70
- with clozapine, 67t, 69-70
- with ziprasidone, 90

## Self-care, in symptomatology of schizophrenia, 25

## Serentil. See also *Mesoridazine*.

- in conventional antipsychotic therapy, 36t

## Seroquel. See also *Quetiapine*.

- adverse effects, 79-82, 80t
- dosing information for, 56-57t, 78-79
- history, 77
- in SGAD therapy, 37t
- mechanism of action, 77
- pharmacokinetics, 79
- studies of, 77-78

## Serotonin hypothesis of psychosis, 19

## Serotonin receptor antagonism

- adverse effects of, 122t
- effect of, on satiety, 148
- in management of aggressive behavior, 172
- in sexual dysfunction, 106t
- role of, in schizophrenia, 19

## Serotonin receptor binding, role of, in antipsychotic drug activity, 19, 53

## Sertindole

- in new developments for treating schizophrenia, 250
- weight gain with, 151

## Sertraline

- effect of, on metabolism of antipsychotic drugs, 231t
- in schizoaffective disorder, 223
- in schizophrenia with depression, 223

## Sexual dysfunction

- treatment options for, 109t
- with antipsychotic therapy, 129
- in CATIE study, 108
- in SGAD therapy, 107-109
- mechanism of, in antipsychotic therapy, 103, 106, 106t
- treatment considerations in, 40-41t

## SGADs. See *Second-generation antipsychotic drugs*.

## Sibutramine, use of, in patients on antipsychotic drugs, 155

## Sildenafil, in treatment of sexual disturbance in antipsychotic therapy, 109t

## Simpson-Angus Scale (SAS), in evaluation of antipsychotic side effects, 48, 49

## Single photon emission computed tomography (SPECT), in characterization of brain abnormality, 14

## Sinusitis, with risperidone, 84t

## Sleep disturbance

- in symptomatology of schizophrenia, 25
- with clozapine, 66t

## Social aptitude, impairment of, 25t

## Social dysfunction

- cognitive impairment with, 235
- in differential diagnosis, 28t

## Social skills training (SST), in psychosocial rehabilitation, 42

## Somatic delusions, defined, 23t

## Somatic disturbance, in assessment of psychopathology, 44t

## Somnolence

- in antipsychotic-treated children, 215
- with aripiprazole, 61t
- with long-acting risperidone, 193-194
- with olanzapine therapy, 74-75t
- with paliperidone ER, 78t
- with quetiapine, 80t
- with risperidone, 84t
- with ziprasidone, 88t

## Sotalol, contraindicated with ziprasidone, 89, 232

## Sparfloxacin, contraindicated with ziprasidone, 89

## SPECT. See *Single photon emission computed tomography*.

## SST. See *Social skills training*.

## Stabilization therapy. See *Maintenance therapy*.

## Starlix. See *Nateglinide*.

- antidiabetic mechanism of, 164-165t

Stelazine. See also *Trifluoperazine*.  
in conventional antipsychotic therapy, 36t

Strauss, characterization of schizophrenia by, 21

Structural abnormality, 15t

Substance abuse  
as factor in relapse, 241  
with schizophrenia, treatment of, 220-222

Substantia nigra, role in effect of antipsychotic drugs, 16, 17

Sugar-free gum, in hypersalivation, 68t

Suicidal tendency, treatment considerations in, 40-41t

Suicide  
incidence of, in schizophrenia, 173  
increased risk, with conventional therapy, 174  
risk factors for, 174, 175t  
risk of, 27

Sulfonylureas, antidiabetic mechanism of, 164-165t

Superior temporal cortex, role in effect of antipsychotic drugs, 16, 17

Suspiciousness, in assessment of psychopathology, 46t

Sweating  
comparative incidence of, in SGAD therapy, 99t  
with clozapine, 66t

Switching drug therapies  
benefits of, in SGAD therapy, 179  
rationale for, 178-179  
strategies for, 180t

Symptoms of schizophrenia, 13, 25, 25t  
responsiveness to treatment, 31

Syncope  
comparative incidence of, in SGAD therapy, 99t  
with clozapine, 66t  
with olanzapine, 73

Tachycardia  
comparative incidence of, in SGAD therapy, 99t  
in Levenson's diagnostic criteria for NMS, 131t  
with clozapine, 66t, 69  
with olanzapine, 73, 74-75t  
with paliperidone ER, 77, 78t  
with quetiapine, 80t  
with risperidone, 84t  
with ziprasidone, 88t

Tangentiality, in thought disorder, 24t

Tardive dyskinesia  
in schizophrenia with substance abuse, 220-222  
in sexual dysfunction, 106t  
susceptibility to, of elderly patients, 218  
treatment considerations in, 40-41t

Tegmentum, role in effect of antipsychotic drugs, 16, 17

Temporal cortex, impact of functional changes in, 16t

Tension, in assessment of psychopathology, 45t

Terazosin, in hypersalivation, 68t

Texas Implementation of Medication Algorithm, 38  
guidelines for combination therapy in treatment-resistant schizophrenia, 206, 207t

Texas Medication Algorithm Project (TMAP)  
treatment algorithm from, 38  
treatment recommendations of, 35, 38

Thiazolidinediones, antidiabetic mechanism of, 164-165t

Thioridazine  
adverse effects with, 123t  
anticholinergic effects of, 125  
chemical structure of, 118-119  
contraindicated with ziprasidone, 89, 232  
dopamine receptor affinity of, 101  
dosing guidelines for, 120-121t  
effect of, on QTc interval, 111  
effect on cognition by, 237  
in conventional antipsychotic therapy, 36t  
introduced for antipsychotic use, 33  
metabolism, 230t  
orthostatic hypotension with, 124  
weight gain with, 149, 151

Thiothixene  
adverse effects with, 123t  
chemical structure of, 118-119  
dosing guidelines for, 120-121t  
in conventional antipsychotic therapy, 36t  
introduced for antipsychotic use, 33

Thioxanthenes  
as subclass of antipsychotic medication, 116, 118-119  
chemical structure of, 118-119

Thorazine. See also *Chlorpromazine*.  
in conventional antipsychotic therapy, 36t

Thought blocking

Thought broadcasting, defined, 23t

Thought disorder  
characteristics of, 22, 24t  
in assessment of psychopathology, 47t  
with functional brain changes, 16t

Thought insertion, defined, 23t

TIMA. See *Texas Implementation of Medication Algorithm*.

TMAP. See *Texas Medication Algorithm Project*.

Toothache, with risperidone, 84t

Topiramate  
in combination therapy for treatment-resistant schizophrenia, 207t  
use of, in patients on antipsychotic drugs, 155

Torsades de pointes  
with clozapine therapy, 69  
with thioridazine, 124

Traditional antipsychotic drugs. See *Conventional therapy*.

- Transaminase elevations  
 with olanzapine, 73  
 with quetiapine, 81
- Transmitter disturbance, role of, in schizophrenia, 18-19
- Treatment goals, 35, 39
- Treatment options. See also *Conventional therapy, Second-generation antipsychotic drugs*.  
 guidelines of the American Psychiatric Association, 35  
 guidelines of the TMAP, 35  
 historical approach, 33-34
- Treatment-resistant schizophrenia  
 clozapine in, 197  
 combination therapy for, 205-208  
 criteria for diagnosis of, 198-199, 199t  
 management guidelines for, 210-211t  
 monotherapy for, 200-205  
 vs chronicity, 197-198
- Tremor  
 with aripiprazole, 61t  
 with clozapine, 66t  
 with olanzapine therapy, 74-75t
- Tricyclic antidepressants  
 association with aggressive behavior, 172t  
 effect of, on metabolism of antipsychotic drugs, 231t
- Trifluoperazine  
 adverse effects with, 123t  
 anticholinergic effects of, 125  
 dosing guidelines for, 120-121t  
 in conventional antipsychotic therapy, 36t
- Trilafon. See also *Perphenazine*.  
 in conventional antipsychotic therapy, 36t
- Tuberoinfundibular tract  
 effect of antipsychotic drugs on, 18  
 role in effect of antipsychotic drugs, 16, 17
- Uncooperativeness, in assessment of psychopathology, 47t
- Undifferentiated type, in categorization of schizophrenia, 27
- Upper respiratory infection, with risperidone, 84t
- Urecholine. See *Bethanechol*.
- Urinary incontinence  
 with clozapine, 67t, 71  
 with olanzapine therapy, 74-75t
- Urinary tract infection, with olanzapine therapy, 74-75t
- V-AKT murine thymoma viral oncogene homolog 1, in vulnerability for schizophrenia, 21t
- Valproate  
 in combination therapy for treatment-resistant schizophrenia, 207t  
 in prevention of seizure with clozapine therapy, 70  
 in schizoaffective disorder, 223  
 in schizophrenia with depression, 223
- Vascular dementia, psychotic symptoms with, in the elderly, 217
- Vasoconstriction  
 management of, 124  
 with conventional therapies, 124
- Ventricular dilation, associated with schizophrenia, 15t
- Ventricular function, effects of antipsychotic drugs on, 109-110, 111t
- VEOS. See *Very-early-onset schizophrenia*.
- Verapamil, effect of, on metabolism of antipsychotic drugs, 231t
- Vertigo, comparative incidence of, in SGAD therapy, 99t
- Very-early-onset schizophrenia, 214
- Visual disturbance  
 comparative incidence of, in SGAD therapy, 99t  
 with clozapine, 66t  
 with risperidone, 84t
- Vocational support  
 in psychosocial rehabilitation, 42
- Vomiting  
 with aripiprazole, 61t  
 with clozapine, 67t  
 with olanzapine therapy, 74-75t  
 with risperidone, 84t
- Weight gain  
 clinical consequences of, 147t  
 comparative incidence of, in SGAD therapy, 99t, 100t  
 in antipsychotic-treated children, 215  
 in sexual dysfunction, 106t  
 management of, in treated patients, 152-156, 154t  
 mechanism of, 148-149  
 minimal with paliperidone ER, 76  
 with antipsychotic medications, 149-152, 150, 151, 153t  
 with antipsychotic therapy, 128  
 with clozapine, 66t, 70  
 with long-acting risperidone, 193-194  
 with olanzapine, 73, 74-74t  
 with quetiapine, 80t, 81  
 with risperidone, 85-86
- Word salad, defined, in thought disorder, 24t
- Xenical See *Orlistat*.
- Xerolube, in treatment of anticholinergic effects of conventional antipsychotics, 125
- Ziprasidone  
 adverse effects, 87-90, 88t  
 as first-line therapy, by co-morbidity, 40-41t  
 chemical structure of, 55  
 comparative efficacy of, 94-97, 96t  
 comparative incidence of extrapyramidal side effects in, 98, 102, 104  
 comparative side effects of, 98, 99t, 100t

Ziprasidone (*continued*)

- discontinuation rates, in CATIE, 179
- dopamine receptor affinity of, 101
- dosing information for, 56-57t, 87
- drug interactions, contraindications with, 232-233, 232t
- effect of, on glucose homeostasis, 162
- effect of, on QTc interval, 110-112, 111
- effect on cognition by, 237
- efficacy, 86-87
- factors affecting absorption, 228
- history, 86
- in adolescents and children with schizophrenia, 214, 215-216
- in CATIE trial, 94
- in combination therapy for treatment-resistant schizophrenia, 207t
- in long-term maintenance therapy, 178
- in management of acute psychosis, 170-171t
- in SGAD therapy, 37t
- in treatment algorithm, 38
- in treatment-resistant schizophrenia, 204
- in young patients, 97
- lipid changes with, 165
- mechanism of action, 86
- metabolism of, 229-233, 230t, 233
- pharmacokinetics, 87
- profiles for receptor binding, 54
- receptor affinity of, 95t
- sedative effect, in CATIE trial, 112
- weight gain with, 150, 151, 152t
  - in CATIE trial, 153t

Zotepine, in new developments for treating schizophrenia, 250

Zyprexa. See also *Olanzapine*.

- adverse effects of, 73, 74t
- dosing information for, 56-57t, 72
- efficacy, 71
- history of, 71
- in management of acute psychosis, 170-171t
- in SGAD therapy, 37t
- mechanism of action, 71
- pharmacokinetics, 72
- vs haloperidol, 71-72
- studies of, 86-87
  - vs haloperidol, 87